Toward understanding the molecular architecture of a glycogen-committed PP1/PTG holoenzyme: a putative target for lafora disease
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Lafora disease (LD), a fatal incurable neurodegenerative disorder characterized by teenage-onset progressive epilepsy, due to mutations in the EPM2A and EPM2B genes encoding laforin and malin, respectively.The pathophysiological status is correlated to the accumulation of insoluble polyglucosans in brain, determined by an increased glycogen production.In healthy brain cells, the malin/laforin E3-ligase complex regulates, among others, the degradation of PTG (Protein Targeting to Glycogen), a scaffolding protein involved in the activation of glycogen synthesis.PTG carries the type 1 protein phosphatase (PP1) to its substrates: glycogen synthase (GYS) and glycogen phosphorylase (PYG).At the molecular level, loss-of-function mutations in laforin or malin cause PTG accumulation, leading to abnormal glycogen aggregation and formation of neurotoxic Lafora bodies (LB) that drive neurodegeneration.
Fields of Study & Subjects
Glycogen Storage Diseases and Myoclonus
Biomedical Research and Pathophysiology
Metabolism
Diabetes
and Cancer
Publication details
- Journal / source
- Acta Crystallographica Section A Foundations and Advances
- Volume
- 81
- Issue
- a1
- Pages
- e10–e10
- Publication date
- 30 March 2026
- Language
- EN